Bristol-Myers seeks Japanese approval of all-oral HCV regimen

Bristol-Myers Squibb Co. (NYSE:BMY) submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for an interferon- and ribavirin-free oral regimen of daclatasvir ( BMS-790052) and asunapr...